Immunocore Holdings plc: 2025 Annual Report Highlights

Immunocore Holdings plc delivered a year of significant progress and strategic investment in 2025, as detailed in its annual report for the fiscal year ended December 31, 2025.

Business Overview: Immunocore Holdings plc (IMCR), a biotechnology leader, develops innovative T-cell receptor (TCR) immunotherapies. These novel treatments harness the body's immune system to identify and destroy diseased cells, primarily focusing on cancer and infectious diseases. The company is incorporated in England and Wales and trades on the Nasdaq Stock Market.

Financial Performance for Fiscal Year 2025: Immunocore achieved significant growth and made strategic investments in 2025:

• Total Revenue reached approximately $250 million, a substantial increase from the prior year. Strong commercial performance of their flagship product, Kimmtrak (tebentafusp), primarily drove this growth.
• The company reported a net loss of $120 million. This improved from the previous fiscal year as increasing product sales helped offset ongoing research and development costs.
• Research and Development (R&D) expenses totaled approximately $180 million, underscoring their commitment to advancing a robust clinical pipeline.
• Selling, General, and Administrative (SG&A) expenses were approximately $100 million, supporting global commercialization and corporate operations.

Management Discussion (MD&A Highlights): Management highlighted Kimmtrak's successful commercialization as the main driver of revenue growth. This success helped offset substantial investments in the company's expanding clinical pipeline. The improved net loss resulted from rising product sales and disciplined expense management. Immunocore's strategy focuses on advancing its ImmTAX® platform and expanding lead product candidates' indications, all while managing operational expenses to support long-term growth.

Financial Health: Immunocore maintained a strong financial position, ending the year with approximately $450 million in cash and cash equivalents. This provides a solid financial runway for future operations and pipeline development. The company reported a manageable level of long-term debt, mainly from strategic financing arrangements, which did not significantly affect its overall liquidity or financial flexibility. While still negative due to R&D investments, cash flow from operations improved, driven by Kimmtrak sales.

Future Outlook: Immunocore's strategy focuses on three key areas: maximizing Kimmtrak's global potential, rapidly advancing its extensive clinical pipeline, and exploring new targets and uses for its ImmTAX® platform. The company reaffirmed its commitment to ongoing R&D investment and commercial expansion. Management expressed confidence in Kimmtrak's continued growth and the pipeline's potential to create future value.

Competitive Position: Immunocore operates in a highly competitive and rapidly evolving biotechnology landscape. Its competitive edge stems from its proprietary ImmTAX® platform, which allows it to develop novel bispecific T-cell receptor (TCR) immunotherapies. Kimmtrak, for example, is a first-in-class treatment for metastatic uveal melanoma. The company stands out because its unique approach targets proteins inside cells. This expands the range of diseases it can treat beyond what traditional antibody-based therapies can reach. Key competitors include established pharmaceutical companies and other biotech firms developing cancer and infectious disease treatments, especially those focused on T-cell therapies. To maintain its competitive edge, Immunocore relies on continuous innovation, successful clinical development, intellectual property protection, and effective commercialization.

Risk Factors: Despite strong progress, investors should be aware of inherent risks common to the biotechnology sector. These include uncertainties in clinical trial success, regulatory approval processes, intense competition, intellectual property protection, the need for significant capital to fund ongoing research and development, and potential product liability claims.

Product & Pipeline Highlights:

• Kimmtrak (tebentafusp): This first-in-class bispecific T-cell engager continued its strong commercial growth, treating metastatic uveal melanoma (mUM) and achieving increasing market penetration and patient access worldwide.
• Clinical Pipeline: Immunocore significantly advanced its pipeline of novel TCR immunotherapies. Key programs include:
  • IMC-F106C (PRAME-targeted): This candidate progressed through Phase 2 clinical trials for multiple solid tumor indications, including non-small cell lung cancer (NSCLC), ovarian cancer, and melanoma, showing promising early data.
  • IMC-P115C (PIWIL1-targeted): This candidate continued in Phase 1 development for various solid tumors, broadening the company's target portfolio.
• Immunocore's pipeline strategically focuses on cancers with high unmet medical needs, utilizing its proprietary ImmTAX® platform.

Market Position & Corporate Status: As of December 31, 2025, Immunocore's market capitalization stood at approximately $1.8 billion. The company had approximately 51 million shares outstanding as of January 31, 2026. The SEC classifies Immunocore as a "large accelerated filer" and a "well-known seasoned issuer." These designations reflect its significant market capitalization, established reporting history, and financial stability, generally indicating higher transparency and investor confidence.

In summary, Immunocore's 2025 annual report portrays a company in a strong growth phase. It is driven by a successful commercial product and a promising pipeline, while effectively navigating the complexities of drug development and commercialization.